The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GWRE, VXRT and LX
Back to Newsroom
Mentioned in this Article

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GWRE, VXRT and LX

Monday, September 21, 2020 11:00 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Guidewire Software, Inc. (NYSE:GWRE)
Class Period: March 6, 2019 - March 4, 2020
Lead Plaintiff Deadline: September 23, 2020

Guidewire Software, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's transition to the cloud was not going well; (2) that Guidewire's cloud-based products needed to be improved to meet customer needs and catch up with rival systems; (3) that the Company's failed transition to the cloud was also hurting Guidewire's traditional on-premise business; and (4) as a result, Guidewire's revenue guidance, including guidance principally based on significantly increasing demand for the Company's cloud-based products, was baseless and unattainable.

Learn about your recoverable losses in GWRE: http://www.kleinstocklaw.com/pslra-1/guidewire-software-inc-loss-submission-form?id=9440&from=1

Vaxart, Inc. (NASDAQ:VXRT)
Class Period: June 25, 2020 - July 25, 2020
Lead Plaintiff Deadline: October 23, 2020

The VXRT lawsuit alleges that Vaxart, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.

Learn about your recoverable losses in VXRT: http://www.kleinstocklaw.com/pslra-1/vaxart-inc-loss-submission-form?id=9440&from=1

Lexinfintech Holdings, Ltd. (NASDAQ:LX)
This lawsuit is on behalf of shareholders who purchased or otherwise acquired: (a) Lexin American depositary shares pursuant and/or traceable to the Company's initial public offering conducted on or about December 21, 2017; or (b) Lexin securities between December 21, 2017 and August 24, 2020.
Lead Plaintiff Deadline: November 9, 2020

According to the complaint, Lexinfintech Holdings, Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) LexinFintech reported artificially low delinquency rates by giving borrowers in default new funds to make payments; (2) the Company's business model exposes shareholders to enormous losses by prioritizing Chinese lenders for off-balance sheet loans; (3) the Company exaggerated its user base; (4) the Company was facilitating direct peer to peer lending contrary to Chinese law; (5) the Company engaged in undisclosed related party transactions; (6) the Company lacked adequate internal controls; and (7) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in LX: http://www.kleinstocklaw.com/pslra-1/lexinfintech-holdings-ltd-loss-submission-form?id=9440&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

The Klein Law Firm
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: